Patient Support Strategy by Lifecycle Stage: Launch, Growth, Maturity, and Loss of Exclusivity

Today's guest post comes from Kristen Magee, Vice President of Methodology & Enablement at AssistRx.

Kristen explains why patient support programs (PSPs) need to evolve as products move from launch through growth, maturity, and loss of exclusivity. She outlines how manufacturers can recalibrate the balance of technology, automation, and human support at each stage to improve efficiency while maintaining strong patient and healthcare provider experiences.

To learn more about AssistRx's approach to patient support across the product lifecycle, download the AssistRx lifecycle playbook suite.

Read on for Kristen's insights.

Why GoodRx Is Built for the AI-Driven Patient Journey

Today's guest post comes from Divya Iyer, SVP, Head of Revenue, Pharma Direct at GoodRx.

Divya examines how AI-powered search and conversational tools are reshaping the way patients research treatments and prescription costs before ever reaching a brand's website. She argues that pharmaceutical manufacturers must rethink their direct-to-consumer (DTC) strategies to ensure treatment information is discoverable, trusted, and connected to actionable next steps.

Learn more about GoodRx's approach to AI discoverability.

Read on for Divya's insights.

Fixing the Front Door Isn’t the Same as Fixing Time to Therapy

Today's guest post comes from Tom Traylor, Senior Vice President of Pharmacy Operations at CareMetx.

Tom examines how intake speed and time to therapy relate to each other in specialty pharmacy programs. He describes how bringing pharmacy connectivity to the front of the patient journey can support faster benefit verification, clearer affordability answers, and shorter time to therapy.

To learn more about CareMetx's pharmacy model, download their guide, The Hidden Cost of the Hub-to-Pharmacy Handoff (and How to Close the Gap).

Read on for Tom's insights.

BlinkRx Insights: Beyond the Hub - Rethinking the Prescription Journey

Today's guest post comes from Geoffrey Chaiken and Matthew Chaiken, Co-founders of BlinkRx.

Geoffrey and Matthew examine how efforts to improve patient access have contributed to an increasingly fragmented prescription journey. They suggest that a more integrated approach can reduce complexity, improve visibility and control for manufacturers, and create a simpler path to therapy for patients.

To learn more about the BlinkRx Prescription Journey Management Platform, visit BlinkRx.

Read on for Geoffrey and Matthew's insights.

Medicare, Medicaid, and Reverification: What Patient Support Programs Need to Know Before January 2027

Today's guest post comes from Bryce Aronson, Director of Business Development at AssistRx.

Bryce covers three considerations taking effect in January 2027—the end of Medicare Part D premium support, a faster Medicaid redetermination timeline, and the shift away from once-a-year reverification—and what they mean for patient support programs. He explores how affordability solutions can help reduce coverage disruptions, minimize unnecessary PAP utilization, and maintain continuity of therapy throughout the transition.

To learn more about AssistRx's affordability solutions, access their webinar, State of Patient Support 2026: Turning Regulatory Policy, AI and Direct-to-Patient Pressure into Program Strategy.

Read on for Bryce's insights.

Invisible Work of Rare Pharmacy Delivers Highly Visible Patient Outcomes

Today's guest post comes from Jay Weaver, VP, Payer Solutions at PANTHERx^® Rare.

Jay describes the clinical and operational work that often happens behind the scenes at a Rare Pharmacy. He explains how these capabilities—including greater personalization, real-world evidence, and specialized clinical expertise—can support therapeutic success and help payers assess the value of Rare Pharmacy.

To learn more about the PANTHERx approach to Rare Pharmacy, download their guide, Five Criteria for Payers to Evaluate a Rare-Focused Specialty Pharmacy.

Read on for Jay's insights.

Hub Transitions Need Proven Plans, Smart Scale-Up

Today's guest post comes from Josh Marsh, Vice President and General Manager at Cardinal Health Sonexus™ Access and Patient Support.

Josh examines the risks manufacturers take when transitioning a patient services hub from one vendor to another. He argues that scaling with a proven, flexible blueprint can help hubs with speed, patient continuity, and confident decision-making.

To learn more, download Cardinal Health Sonexus™ Access and Patient Support's framework: 5 Questions Every Manufacturer Should Ask Before a Hub Transition.

Read on for Josh's insights.

A System of Record, or a System of Learning?

Today's guest post comes from Scott Filosi, Chief Commercial Officer at Valeris.

Scott explores how patient access organizations can move beyond simply tracking the patient journey to using real-time insights to improve it. He argues that connecting commercial strategy, market access, payer intelligence, and patient services can speed access to therapy, improve decision-making, and enhance the patient experience.

To learn more, download Valeris’ white paper: The Unified Ecosystem: How Valeris Integrates Intelligence and Execution for Better Patient Outcomes.

Read on for Scott's insights.

The Industry Doesn't Have an Access Collaboration Problem. It Has an Accountability Problem.

Today's guest post comes from Jen Norton, President, Market Access & Value at EVERSANA.

Jen examines why fragmented ownership across development, regulatory, pricing, distribution, and field functions undermines access at launch. She argues that naming a single accountable owner for the access outcome can close "access debt" earlier, reduce pre-launch friction, and turn coverage into real patient access.

Learn more about EVERSANA's approach to access.

Read on for Jen's insights.

Direct-to-Patient: Transforming the Manufacturer Access Model

Today's guest post comes from Chip Parkinson, CEO at Gifthealth.

Chip discusses how Direct-to-Patient (DTP) models can transform the manufacturer access model for prescription therapies. He argues that a tech-plus-touch, end-to-end approach can improve patient access, protect manufacturer economics, and increase brand trust and loyalty.

Learn more about Gifthealth.

Read on for Chip's insights.

Direct-to-Consumer Shouldn't Always Mean Direct-To-Mail-Order: Why Fulfillment Choice Matters

Today's guest post comes from Divya Iyer, SVP, Head of Revenue, Pharma Direct at GoodRx.

Divya examines why direct-to-consumer strategies shouldn't default to mail-order as the endpoint for every program. She argues that preserving patient choice between retail pickup and home delivery can reduce friction, improve therapy initiation, and strengthen the overall patient experience.

To learn more about GoodRx's Pharma Direct solution, visit GoodRx Pharma Direct.

Read on for Divya's insights.

When Access Tightens, Prior Authorization Execution Becomes the Differentiator

Today's guest post comes from Megan Wetzel, Vice President of Product, Access and Affordability at CoverMyMeds.

Megan examines how prior authorization execution has become a strategic differentiator for biopharma brands as formulary changes and expanding utilization management put more pressure on access. She argues that building consistent, scalable prior auth execution can reduce therapy delays, improve determination time, and strengthen brand performance across the product lifecycle.

To learn more about CoverMyMeds' prior authorization solution, download their case study: From Decline to Growth: How One Brand Expanded Access in Late Lifecycle.

Read on for Megan's insights.

BlinkRx Insights: The Questions Manufacturers Wish They Had Asked Before Selecting a Patient Services Partner

Today’s guest post comes from Geoffrey Chaiken and Matthew Chaiken, Co-founders of BlinkRx.

Geoffrey and Matthew examine the important role of patient services providers. They suggest several questions manufacturers can ask when evaluating a patient services partner’s technology infrastructure, pharmacy network design, data visibility, and operational capabilities.

Click here to learn more about BlinkRx’s patient services solution.

Read on for Geoffrey and Matthew’s insights.

The Digital Front Door to Specialty Therapy May Not Be a Specialty Pharmacy

Today’s guest post comes from Nareda Mills, President of Patient Solutions at Inizio Engage.

Nareda examines how growing access complexity is reshaping specialty commercialization. She explores the emerging role of Non-Dispensing Pharmacies (NDPs) and argues that by improving coordination, visibility, and patient engagement, they can accelerate time-to-therapy and create a more seamless access experience.

Click here to learn more about Inizio Engage’s hub services.

Read on for Nareda’s insights.

Pharmacy Copay Misuse: The Multi-Billion Dollar Issue Hiding In Plain Sight

Today’s guest post comes from Stephen Hom, Co-Founder, EVP & Chief Operating Officer of RIS Rx.

Drawing on RIS Rx’s proprietary data and case studies, Stephen highlights patterns that can undermine patient support program effectiveness. He argues that a more data-driven approach can help manufacturers identify hidden risks, improve program performance, and ensure that affordability resources reach the patients they are intended to support.

Request a complimentary analysis from RIS Rx.

Read on for Stephen’s insights.

Drugs, Discounts and Data: Crafting Sustainability in an Imperfect System

Today’s guest post comes from Angie Franks, Chief Executive Officer at Kalderos.

As Angie explains, the industry still lacks the transparency needed to effectively manage where discounts occur and how funds move across stakeholders. She argues that improving visibility and coordination across the ecosystem is essential to building a more sustainable and accountable model for both innovation and patient support.

To learn more, register for Kalderos’ free webinar on June 23, 2026:
GTN Oversight: A New Standard of Transparency Is Here.

Read on for Angie’s insights.

Protecting Gross-to-Net Performance Through Single-Channel Ecosystems

Today’s guest post comes from Peter Darch, SVP of Strategy and Operations at PHIL Inc.

Peter explains that growing pressure on drug pricing is exposing structural inefficiencies in gross-to-net (GTN) across traditional distribution channels. He argues that single-channel ecosystems can better coordinate affordability, coverage, and dispensing, improving both patient outcomes and brand performance.

Click here to learn more about PHIL’s technology solution for brands.

Read on for Peter’s insights.

The Hidden Costs of Over-Customizing Your Hub Technology Stack

Today’s guest post comes from George Moore, Chief Product and Technology Officer at CareMetx.

George argues that customer relationship management (CRM) program customization delivers short-term workflow gains at the expense of long-term scalability, integration simplicity, and upgradeability. He highlights three common pitfalls and offers an approach on how to avoid them.

To learn more, download CareMetx’s Guide to Building an Agile, Scalable Hub Architecture.

Read on for George’s insights.

Where Gross-to-net Pressure Actually Lives After Launch

Today’s guest post comes from Cindy Baksh, Chief Product Officer at ConnectiveRx.

Cindy explains that many gross-to-net (GTN) exposures now occur at the claim level, where evolving payer tactics, pharmacy economics, and copay complexity create unpredictable leakage. She argues that manufacturers must augment downstream review with real-time visibility and intervention to protect both revenue and patient access.

To learn more, register for ConnectiveRx’s free webinar on June 17: Gross-To-Net FOMO: What GTN Dangers Are You Missing Post-Launch?

Read on for Cindy’s insights.

Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer Channels

Today’s guest post comes from Laura Jensen, Chief Commercial Officer and President, Pharma Direct at GoodRx.

Laura suggests that manufacturers must move beyond payer-centric models toward integrated, direct-to-consumer and employer channel strategies that connect pricing, demand, and fulfillment. She argues that this approach will help manufacturers convert patient intent into therapy initiation while expanding access at scale.

To learn more about GoodRx’s pharma solutions, visit GoodRx Pharma Direct.

Read on for Laura’s insights.